TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06215794

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Nerve Block
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
Study: NCT05788107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX51
Description: anti-OX40 tetravalent agonistic humanized monoclonal antibody
Study: NCT06135116

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
Description: Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
Description: Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
Description: Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab.
Study: NCT06738849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkiYou V2
Description: Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment.
Study: NCT06739668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pascal device
Description: The study devices consist of a tabletop Console with user interface and a head-worn applicator (Headset) that is connected via coaxial cable. The Headset is positioned on the head per instructions, and then the study subject powers on the device by pressing the power button and initiates a 15-minute treatment by pressing the start button. LED lights on the console count down during the treatment to indicate time remaining and, once the treatment is complete, the device automatically powers off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device will look identical to the active device and will have the same indicator lights and sounds, but will not emit magnetic field therapy.
Study: NCT05776927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol Xinafoate / Fluticasone Propionate
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVM149
Description: Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol Xinafoate / Fluticasone Propionate
Description: Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-In Medication
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Run-In Medication
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication
Description: Salbutamol 100μg / Albuterol 90μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Medication
Description: Salbutamol 100μg / Albuterol 90μg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept 1 Device
Description: Concept1 (Breezhaler) used for QVM149 and placebo delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Concept 1 Device
Description: Concept1 (Breezhaler) used for QVM149 and placebo delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Girohaler
Description: Girohaler for Comparator and Placebo delivery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Girohaler
Description: Girohaler for Comparator and Placebo delivery.
Study: NCT04161599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime (750mg) I.V
Description: Extra dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime (750mg) I.V
Description: Extra dosage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic Surgery
Description: Colonic Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Surgery
Description: Colonic Surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 750mg oral
Description: Oral prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750mg oral
Description: Oral prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG Oral Tablet [Flagyl]
Description: Oral prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 MG Oral Tablet [Flagyl]
Description: Oral prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 1 g Intravenous
Description: IV prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 g Intravenous
Description: IV prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 1,5 g Intravenous
Description: IV prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1,5 g Intravenous
Description: IV prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral
Description: Laxative for bowel cleansing
Study: NCT04716413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dsuvia
Description: Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
Study: NCT06336122

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Weekly
Description: Peer participants will be contacted by peer coaches on a weekly basis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Weekly
Description: Peer participants will be contacted by peer coaches on a weekly basis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Biweekly
Description: Peer participants will be contacted by peer coaches on a bi-weekly basis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Biweekly
Description: Peer participants will be contacted by peer coaches on a bi-weekly basis
Study: NCT05921422

Intervention type: OTHER
Intervention: Cognitive assessment
Description: All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD).

Intervention type: OTHER
Intervention: Cognitive assessment
Description: All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD).
Study: NCT06002256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mostafa Maged maneuver
Description: While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bimanual uterine compression
Description: the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
Study: NCT05170334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
Study: NCT06240988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: Modified Constraint Induced Movement Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Technique
Description: Motor Imagery Technique
Study: NCT04558489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPR + GMI
Description: The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
Study: NCT06645821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVO101
Description: EVO101 topical cream 0.1%
Study: NCT05045404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
Description: Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV
Study: NCT06047132

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivaru biomarkers
Description: C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
Study: NCT06513156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)
Description: Integrated medication for opioid use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavSTAR-CHOICE (NS)
Description: Patient-centered social support intervention including motivational interviewing and patient navigation designed to overcome the barriers in accessing the recommended follow-up opioid use disorder treatment and medical care services for 6 months.
Study: NCT04767854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA school
Description: Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OA school
Description: Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Training mobile health application
Description: Individually tailored home exercise programs delivered through a mobile health application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Individually tailored exercise programs conducted in weekly supervised individual or group sessions
Study: NCT05893069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: oral oxandrolone for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo for 12 weeks
Study: NCT05255237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: 75mg BID
Study: NCT05619380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
Study: NCT04645134

Intervention type: BEHAVIORAL
Intervention: Brain Health Assessments
Description: The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.

Intervention type: BEHAVIORAL
Intervention: Brain Health Assessments
Description: The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
Study: NCT06191302

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.

Intervention type: OTHER
Intervention: Online questionaire
Description: The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.

Intervention type: OTHER
Intervention: Online questionaire
Description: The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.
Study: NCT06260475

Intervention type: PROCEDURE
Intervention: Aortobifemoral bypass
Description: Open surgery with aortic and iliac reconstruction

Intervention type: PROCEDURE
Intervention: aortoiliac stenting
Description: Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand
Study: NCT06404840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab (400 mg, iv, d1, qw)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG chemotherapy
Description: (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
Study: NCT05477992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular embolization
Description: Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
Study: NCT05674292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Violet Zerona Z6
Description: 405nm violet diode low level laser device
Study: NCT04589403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPT101
Description: 15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT101
Description: 15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40